AOBIM/ABIM EXAM QUESTIONS WITH
100% CORRECT ANSWERS | LATEST
VERSION 2025/2026.
Howell Jolly bodies - ANS asplenia, splenectomy
Heinze bodies - ANS g6PD deficiency
Bite cells - ANS g6pd deficiency
Which leukemia/lymphoma associated with autoimmune hemolytic anemia - ANS CLL
Hemochromtosis: susceptible to these infections - ANS Vibrio, listeria, Yersinia
Four tests to evaluate a bleeding disorder - ANS PTT, PT, platelet level, platelet function test
(ADP, epinephrine, collagen stimulation)
ITP: first and second line treatments? - ANS 1st line: Steroids; 2nd line: IVIG
Treatment for atypical HUS - ANS Eculizumab. inhibits terminal complement cascade
Goal INR for argatroban treatment for HIT II - ANS INR >4
1 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED
, Post transfusion purpura: when does it occur? - ANS One week after; no schistocytes on
peripheral smear; treatment: IVIG
2 most common types of vWD? - ANS Type 1 and Type 2a
What determines the risk of bleeding - ANS Dependent on Factor VIII levels. >5% low risk vs.
<1% high risk.
What is the clinical presentation of Factor XI deficiency? - ANS Mucosal bleeding. Treatment:
FFP, recombinant Factor XI, or desmopressin
What is the clinical presentation of Factor XII deficiency? - ANS Increased PTT. No bleeding.
Special test to diagnose Factor XIII deficiency? - ANS Clot lysis assay
Which blood product administration has a higher incidence of bacterial infection and why? -
ANS Platelet transfusion due to it being stored at room temperature
How to treat hyperviscosity syndrome in ALL? - ANS Leukopheresis and hydroxyurea
What physical findings are seen in ALL patients? - ANS Enlarged LNs, splenomegaly,
hepatomegaly, enlarged testicles
What ALL cytogentic abnormality is associated with poor prognosis? - ANS 9:22 translocation
What are the main differences between ALL and MPD? - ANS ALL has new cells/blasts
whereas MPD has clonal expansion of current cells
What is 5q- syndrome? - ANS A subset of MDS, notably females with thrombocytosis.
Favorable prognosis. Tx imatinib
2 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED
100% CORRECT ANSWERS | LATEST
VERSION 2025/2026.
Howell Jolly bodies - ANS asplenia, splenectomy
Heinze bodies - ANS g6PD deficiency
Bite cells - ANS g6pd deficiency
Which leukemia/lymphoma associated with autoimmune hemolytic anemia - ANS CLL
Hemochromtosis: susceptible to these infections - ANS Vibrio, listeria, Yersinia
Four tests to evaluate a bleeding disorder - ANS PTT, PT, platelet level, platelet function test
(ADP, epinephrine, collagen stimulation)
ITP: first and second line treatments? - ANS 1st line: Steroids; 2nd line: IVIG
Treatment for atypical HUS - ANS Eculizumab. inhibits terminal complement cascade
Goal INR for argatroban treatment for HIT II - ANS INR >4
1 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED
, Post transfusion purpura: when does it occur? - ANS One week after; no schistocytes on
peripheral smear; treatment: IVIG
2 most common types of vWD? - ANS Type 1 and Type 2a
What determines the risk of bleeding - ANS Dependent on Factor VIII levels. >5% low risk vs.
<1% high risk.
What is the clinical presentation of Factor XI deficiency? - ANS Mucosal bleeding. Treatment:
FFP, recombinant Factor XI, or desmopressin
What is the clinical presentation of Factor XII deficiency? - ANS Increased PTT. No bleeding.
Special test to diagnose Factor XIII deficiency? - ANS Clot lysis assay
Which blood product administration has a higher incidence of bacterial infection and why? -
ANS Platelet transfusion due to it being stored at room temperature
How to treat hyperviscosity syndrome in ALL? - ANS Leukopheresis and hydroxyurea
What physical findings are seen in ALL patients? - ANS Enlarged LNs, splenomegaly,
hepatomegaly, enlarged testicles
What ALL cytogentic abnormality is associated with poor prognosis? - ANS 9:22 translocation
What are the main differences between ALL and MPD? - ANS ALL has new cells/blasts
whereas MPD has clonal expansion of current cells
What is 5q- syndrome? - ANS A subset of MDS, notably females with thrombocytosis.
Favorable prognosis. Tx imatinib
2 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED
